{"id":936784,"date":"2026-02-12T19:52:47","date_gmt":"2026-02-13T00:52:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/"},"modified":"2026-02-12T19:52:47","modified_gmt":"2026-02-13T00:52:47","slug":"nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/","title":{"rendered":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams"},"content":{"rendered":"
\n

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (\u201cNervGen\u201d or the \u201cCompany”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th<\/sup>, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition.<\/p>\n

\u201cOn behalf of the Board of Directors and our NervGen employees, I want to thank Bill for his financial and strategic leadership, as well as extend our sincere gratitude for his unwavering dedication and commitment to the Company,\u201d said Adam Rogers, MD, President and Chief Executive Officer of NervGen. \u201cBill joined us at a critical moment in the lifecycle of the Company six years ago and has been a trusted colleague and advisor. His integrity, thoughtfulness, and commitment to our mission have been invaluable to me personally and to the entire organization. We’re grateful for everything Bill has contributed to NervGen and wish him the best in a well-deserved retirement.\u201d<\/p>\n

\u201cI am honored to have served as Chief Financial Officer of NervGen and to have played a meaningful role in all that we\u2019ve accomplished over the past several years,\u201d Mr. Adams commented. \u201cIt gives me great joy to have helped guide the Company\u2019s dramatic transformation from preclinical and first-in-human studies to a Nasdaq-listed company entering late-stage development for NVG-291, a therapeutic candidate with the potential to significantly impact the lives of so many around the world living with spinal cord injury.\u201d<\/p>\n

\u201cThese past six years at NervGen has been unlike anything else I\u2019ve had the opportunity to work on in my career, and I\u2019m incredibly proud of the financial and operational foundation we\u2019ve built. I believe the Company is well positioned, with a clear path ahead. I look forward to supporting NervGen during this transition and cheering on its continued success in the years to come,\u201d Mr. Adams concluded.<\/p>\n

\n About NervGen Pharma<\/strong>
\n
NervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company\u2019s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen\u2019s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the Phase 1b\/2a CONNECT SCI Study<\/a> in individuals with chronic SCI between 1 to 10 years post-injury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence, and quality of life. The Company\u2019s Phase 1b\/2a CONNECT SCI Study in individuals with subacute SCI is ongoing, alongside preparation for a Phase 3 clinical trial in chronic SCI. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the Company\u2019s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com<\/a> and follow NervGen on X<\/a> and LinkedIn<\/a>.<\/p>\n

\n Contacts<\/strong>
\n
Huitt Tracey, Investors
htracey@nervgen.com<\/a>
604.537.2094<\/p>\n

David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com<\/a>
Ignacio.Guerrero-Ros@russopartnersllc.com<\/a>
858.717.2310<\/p>\n

Adam Rogers, President and CEO
info@nervgen.com<\/a>
778.731.1711<\/p>\n

\n
\n Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/em>
\n <\/strong>\n <\/p>\n

\n Cautionary Note and Forward Looking-Statements <\/strong>
\n
This news release may contain \u201cforward-looking information\u201d and \u201cforward-looking statements\u201d within the meaning of applicable securities laws (collectively, \u201cforward-looking statements\u201d). Such forward-looking statements herein include but are not limited to, the Company\u2019s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words \u201cmay\u201d, \u201cwill\u201d, \u201cwould\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201cexpect\u201d, \u201cplan\u201d, \u201cintend\u201d, \u201ctrend\u201d, \u201cindication\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cestimate\u201d, \u201cpredict\u201d, \u201clikely\u201d or \u201cpotential\u201d, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the Company’s plans to engage and appoint a successor CFO; the expected timing and nature of the CFO transition; Mr. Adams’ continued support in an advisory capacity; the Company\u2019s potentially best-in-class candidate, NVG-291; the potential broad therapeutic applications of NVG-291; the future growth of the Company; the Company\u2019s mission to transform the lives of individuals living with spinal cord injury; the Company\u2019s pursuit to revolutionize the treatment paradigm for neurotraumatic conditions with significant unmet medical need; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and final results from our Phase 1b\/2a clinical trial of NVG-291 in individuals with spinal cord injury; and the creation of neuroreparative therapeutics to enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management\u2019s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: its ability to obtain future funding on favorable terms, if at all; the accuracy of its financial projections; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Many factors could cause the Company\u2019s actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the “Risk Factors” section of the Company\u2019s most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen\u2019s profile on SEDAR+ at www.sedarplus.ca<\/a> and in NervGen\u2019s Form F-10\/A filed on EDGAR at www.edgar.com. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (\u201cNervGen\u201d or the \u201cCompany”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition. \u201cOn behalf of the Board of Directors and our NervGen employees, I want to thank Bill for his financial and strategic leadership, as well as extend our sincere gratitude for his unwavering dedication and commitment to … <\/p>\n

Continue reading “NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-936784","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (\u201cNervGen\u201d or the \u201cCompany”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition. \u201cOn behalf of the Board of Directors and our NervGen employees, I want to thank Bill for his financial and strategic leadership, as well as extend our sincere gratitude for his unwavering dedication and commitment to … Continue reading "NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T00:52:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams\",\"datePublished\":\"2026-02-13T00:52:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/\"},\"wordCount\":1178,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/\",\"name\":\"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=\",\"datePublished\":\"2026-02-13T00:52:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/","og_locale":"en_US","og_type":"article","og_title":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - Market Newsdesk","og_description":"VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (\u201cNervGen\u201d or the \u201cCompany”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition. \u201cOn behalf of the Board of Directors and our NervGen employees, I want to thank Bill for his financial and strategic leadership, as well as extend our sincere gratitude for his unwavering dedication and commitment to … Continue reading \"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-13T00:52:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams","datePublished":"2026-02-13T00:52:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/"},"wordCount":1178,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/","name":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=","datePublished":"2026-02-13T00:52:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzkzNSM3NDIzNjY3IzIxOTM2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=936784"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936784\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=936784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=936784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=936784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}